Roivant Sciences publishes presentation on brepocitinib Phase 3 results in non-infectious uveitis
ROIV•ROIV•ROIV•ROIV•Roivant Sciences published Phase 3 results showing brepocitinib met the primary and all secondary endpoints in both CLARITY trials. Median time to treatment failure exceeded 48 weeks versus about 12 weeks for placebo, and the company plans an sNDA filing in the first half of 2027.
Brepocitinib met the primary endpoint and all secondary endpoints in both Phase 3 CLARITY trials for non-infectious uveitis. Median time to treatment failure exceeded 48 weeks, versus approximately 12 weeks for placebo, with p<0.0001 in both trials.
Steroid-free quiescence reached 62% at one year, a placebo-adjusted improvement of 41 percentage points. Roivant plans to file a supplemental new drug application for non-infectious uveitis in the first half of 2027.
